David J. Einstein
banner
davidjeinstein.bsky.social
David J. Einstein
@davidjeinstein.bsky.social
Disease Group Leader, BIDMC GU Medical Oncology, Dana-Farber/Harvard Cancer Center
6-7 pm EST: Advanced and Newly Diagnosed subgroups

7-8 pm EST: Ian Travis, PT DPT
@bidmcnews
discussing treatment of urinary incontinence
February 3, 2025 at 4:30 PM
Increasingly I’m seeing it as an exclusion criterion in industry-led trials, esp ADCs. Makes no sense to single this out (unless there’s a taxane comparator arm). Use typical CBC cutoffs and make inclusion criteria as broad as possible.
December 16, 2024 at 1:15 PM
We had a similar exchange here:

ascopubs.org/doi/abs/10.1...
Reply to B. Tombal et al | Journal of Clinical Oncology
ascopubs.org
November 29, 2024 at 6:38 PM